.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Queensland Health
Farmers Insurance
US Army
McKesson
Baxter
UBS
Mallinckrodt
Dow

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,994,220 protect, and when does it expire?


Patent ► Subscribe protects SAVELLA and is included in one NDA. There has been one Paragraph IV challenge on Savella.

This patent has twenty-nine patent family members in twenty-one countries.

Summary for Patent: ► Subscribe

Title:Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s): Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:11/535,237
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-001Jan 14, 2009ABRXYesNo► Subscribe► Subscribe MANAGEMENT OF FIBROMYALGIA
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-002Jan 14, 2009ABRXYesNo► Subscribe► Subscribe MANAGEMENT OF FIBROMYALGIA
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-003Jan 14, 2009ABRXYesYes► Subscribe► Subscribe MANAGEMENT OF FIBROMYALGIA
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-004Jan 14, 2009ABRXYesNo► Subscribe► Subscribe MANAGEMENT OF FIBROMYALGIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel190284► Subscribe
Israel228904► Subscribe
Japan2012193216► Subscribe
Georgia, Republic ofP20125595► Subscribe
European Patent Office2682114► Subscribe
Japan5922515► Subscribe
Japan2015134811► Subscribe
Japan6014702► Subscribe
Japan2009510080► Subscribe
South Korea20080055967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Medtronic
Cantor Fitzgerald
Boehringer Ingelheim
Cipla
Deloitte
Healthtrust
Julphar
Citi
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot